Petra Buechner-Steudel

FOLFOXIRI Plus Panitumumab As First-Line Treatment of <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)

Dominik Paul Modest, Uwe M. Martens, Jorge Riera‐Knorrenschild et al. · Journal of Clinical Oncology · 2019 · 195 citations

Medicine, Oncology, Pharmacotherapy +15

Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials

Dorothea Wagner, Petra Buechner-Steudel, Markus Moehler et al. · British Journal of Cancer · 2009 · 57 citations · Full text

Medicine, Oncology, Pharmacology +17

Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Dorothea Wagner, Petra Buechner-Steudel, A. Wein et al. · Annals of Oncology · 2006 · 13 citations · Full text

Medicine, Oncology, Pharmacotherapy +14